Galectin Therapeutics (Galectin Therapeutics) Cash And Cash Equivalents : $25.66 Mil (As of Dec. 2023)

View and export this data going back to 2002. Start your Free Trial

What is Galectin Therapeutics Cash And Cash Equivalents?

Galectin Therapeutics's quarterly cash and cash equivalents increased from Jun. 2023 ($17.97 Mil) to Sep. 2023 ($20.36 Mil) and increased from Sep. 2023 ($20.36 Mil) to Dec. 2023 ($25.66 Mil).

Galectin Therapeutics's annual cash and cash equivalents declined from Dec. 2021 ($39.65 Mil) to Dec. 2022 ($18.59 Mil) but then increased from Dec. 2022 ($18.59 Mil) to Dec. 2023 ($25.66 Mil).

Galectin Therapeutics Cash And Cash Equivalents Historical Data

The historical data trend for Galectin Therapeutics's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galectin Therapeutics Cash And Cash Equivalents Chart

Galectin Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

47.48

27.14

39.65

18.59

25.66

Galectin Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash And Cash Equivalents	Get a 7-Day Free Trial															18.59	17.80	17.97	20.36	25.66

Galectin Therapeutics Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Galectin Therapeutics (NAS:GALT) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Galectin Therapeutics Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Galectin Therapeutics's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Galectin Therapeutics (Galectin Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galectin Therapeutics Inc (NAS:GALT) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

PHPN:Germany

Address

4960 Peachtree Industrial Boulevard, Suite 240, Norcross, GA, USA, 30071

Website

https://www.galectintherapeutics.com

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its lead galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Executives

Kary Eldred	director	2121 RINGWOOD AVENUE, SAN JOSE CA 95131
Kevin D Freeman	director	712 LAKEWAY DRIVE, KELLER TX 76248
Zordani Richard A. Jr.	director	467 N. COUNTRY RIDGE CT., LAKE ZURICH IL 60047
10x Fund, L.p.	10 percent owner	1099 FOREST LAKE TERRACE, NICEVILLE FL 32578
Elissa J. Schwartz	director	235 SW CHURCH ST., PULLMAN WA 99163
Gilbert F Amelio	director	5835 STRASBOURG COURT, ---, RENO NV 89511
Richard E Uihlein	director, 10 percent owner	12575 ULINE DRIVE, PLEASANT PRAIRIE WI 53158
Pol F Boudes	officer: Chief Medical Officer	C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Joel Lewis	director	12575 ULINE DRIVE, PLEASANT PRAIRIE WI 53158
Gilbert S Omenn	director	AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Harold H. Shlevin	director, officer: Chief Executive Officer	C/O GALECTIN THERAPEUTICS, INC., 4690 PEACHTREE INDUSTRIAL BLVD, STE. 240, NORCROSS GA 30071
Jack W Callicutt	officer: Chief Financial Officer	75 FIFTH STREET NW STE. 313, ATLANTA GA 30308
Marc Rubin	director	C/O TITAN PHARMACEUTICALS, INC., 400 OYSTER POINT BLVD., STE 505, SAN FRANCISCO CA 94080
James C Czirr	director	4908 SOUTH ASHTON COURT, SPOKANE WA 99223
Peter G Traber	director, officer: President and CEO	430 THAMER LANE, HOUSTON TX 77025